Logo image of KTTA

PASITHEA THERAPEUTICS CORP (KTTA) Stock Fundamental Analysis

NASDAQ:KTTA - Nasdaq - US70261F2020 - Common Stock - Currency: USD

2.14  -0.6 (-21.9%)

After market: 2.1 -0.04 (-1.87%)

Fundamental Rating

2

Taking everything into account, KTTA scores 2 out of 10 in our fundamental rating. KTTA was compared to 572 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for KTTA as it has an excellent financial health rating, but there are worries on the profitability. KTTA does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year KTTA has reported negative net income.
In the past year KTTA has reported a negative cash flow from operations.
KTTA Yearly Net Income VS EBIT VS OCF VS FCFKTTA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 -5M -10M -15M

1.2 Ratios

KTTA's Return On Assets of -84.64% is on the low side compared to the rest of the industry. KTTA is outperformed by 70.62% of its industry peers.
With a Return On Equity value of -88.56%, KTTA perfoms like the industry average, outperforming 49.03% of the companies in the same industry.
Industry RankSector Rank
ROA -84.64%
ROE -88.56%
ROIC N/A
ROA(3y)-32.01%
ROA(5y)N/A
ROE(3y)-35.08%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
KTTA Yearly ROA, ROE, ROICKTTA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 -20 -40 -60

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for KTTA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
KTTA Yearly Profit, Operating, Gross MarginsKTTA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 -5K -10K -15K -20K -25K

More info and screens

7

2. Health

2.1 Basic Checks

The number of shares outstanding for KTTA has been reduced compared to 1 year ago.
KTTA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
KTTA Yearly Shares OutstandingKTTA Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 200K 400K 600K 800K 1M
KTTA Yearly Total Debt VS Total AssetsKTTA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 10M 20M 30M 40M 50M

2.2 Solvency

KTTA has an Altman-Z score of -3.22. This is a bad value and indicates that KTTA is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -3.22, KTTA is in line with its industry, outperforming 45.66% of the companies in the same industry.
There is no outstanding debt for KTTA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -3.22
ROIC/WACCN/A
WACCN/A
KTTA Yearly LT Debt VS Equity VS FCFKTTA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 0 20M 40M

2.3 Liquidity

A Current Ratio of 14.81 indicates that KTTA has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 14.81, KTTA belongs to the top of the industry, outperforming 89.38% of the companies in the same industry.
KTTA has a Quick Ratio of 14.81. This indicates that KTTA is financially healthy and has no problem in meeting its short term obligations.
KTTA has a better Quick ratio (14.81) than 89.38% of its industry peers.
Industry RankSector Rank
Current Ratio 14.81
Quick Ratio 14.81
KTTA Yearly Current Assets VS Current LiabilitesKTTA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 10M 20M 30M 40M 50M

More info and screens

0

3. Growth

3.1 Past

The earnings per share for KTTA have decreased strongly by -12.86% in the last year.
EPS 1Y (TTM)-12.86%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%17.2%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
KTTA Yearly Revenue VS EstimatesKTTA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 100K 200K 300K 400K 500K
KTTA Yearly EPS VS EstimatesKTTA Yearly EPS VS EstimatesYearly EPS VS Estimates 2020 2021 2022 2023 -2 -4 -6

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

KTTA reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
KTTA Price Earnings VS Forward Price EarningsKTTA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
KTTA Per share dataKTTA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 10 -10

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

KTTA does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PASITHEA THERAPEUTICS CORP

NASDAQ:KTTA (2/6/2025, 6:24:35 PM)

After market: 2.1 -0.04 (-1.87%)

2.14

-0.6 (-21.9%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-11 2024-08-11/amc
Earnings (Next)N/A N/A
Inst Owners2.87%
Inst Owner Change0%
Ins Owners10.65%
Ins Owner Change0%
Market Cap2.72M
Analysts82.86
Price TargetN/A
Short Float %1%
Short Ratio0.21
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.15
P/tB 0.3
EV/EBITDA N/A
EPS(TTM)-14.38
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-11.65
FCFYN/A
OCF(TTM)-11.65
OCFYN/A
SpS0
BVpS14.03
TBVpS7.15
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -84.64%
ROE -88.56%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-32.01%
ROA(5y)N/A
ROE(3y)-35.08%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 14.81
Quick Ratio 14.81
Altman-Z -3.22
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)1213.67%
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-12.86%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%17.2%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-8.51%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-28.54%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-28.84%
OCF growth 3YN/A
OCF growth 5YN/A